Clinical Trials Logo

Clinical Trial Summary

The purpose is to test whether early central nervous system (CNS) prophylaxis given at the beginning of therapy for young high risk diffuse large B-cell lymphoma (DLBCL) patients is feasible and could reduce the risk of CNS relapses. Early CNS prophylaxis with two courses high dose methotrexate (HD-MTX) in combination with rituximab-cyclophosphamide-doxorubicin-vincristine-prednison (R-CHOP) is followed by four courses of R-CHOP14 and etoposide (E) and one course of HD-Ara-C. In addition the patients will receive three courses of liposomal cytarabine intrathecally. The results will be compared to a recent Nordic CRY-04 study. Shifting of CNS prophylaxis to the beginning of the therapy offers a potential to overcome the subclinical disease and thus reduce the risk of early clinical CNS recurrence. As flow cytometry (FCM) can improve the sensitivity for detecting occult leptomeningeal disease over cytology , FCM from cerebrospinal fluid will be incorporated into the staging procedures.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01325194
Study type Interventional
Source Nordic Lymphoma Group
Contact
Status Completed
Phase Phase 2
Start date March 2011
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Completed NCT03702361 - Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease Phase 4
Completed NCT00405210 - Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer Phase 1
Completed NCT00803244 - Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis (With or Without Asthma) Phase 3
Completed NCT01214798 - A Case of Sesamoid Displacement Causing the First Metacarpophalangeal Joint Locking N/A
Completed NCT00552461 - Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis Phase 2
Terminated NCT01868243 - Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively Phase 2/Phase 3
Completed NCT01323894 - Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling N/A